Zenith Epigenetics and Newsoara Announce Initiation of Phase 2b mCRPC Study Evaluating Combination of ZEN-3694 and Enzalutamide

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Zenith Epigenetics and Newsoara Announce Initiation of Phase 2b mCRPC Study Evaluating Combination of ZEN-3694 and Enzalutamide

posted on Sep 21, 2021 10:43AM

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study Evaluating the Combination of ZEN-3694 and Enzalutamide in mCRPC Patients Who Responded Poorly to Prior Abiraterone Treatment